Renal MRI Biomarkers: The Route to Clinical Adoption

项目摘要/摘要 肾功能磁共振生物标记物在研究和临床实践中未得到充分利用，因为需要 专注于内部专业知识和开发。因此，将解决方案转移到其他中心是 挑战，导致工作大量重复，方法缺乏标准化，以及 在不同中心之间比较结果的困难。这也限制了商业买入，阻碍了 多中心试验的建立，总体上阻碍了这些生物标志物转化为临床 练习一下。我们提议的研讨会(https://www.ismrm.org/workshops/2021/Renal/)旨在弥合这一点 差距。这次研讨会的目的是将国际公认的科学家和临床医生聚集在一起。 目前正在开发和应用先进的肾脏磁共振技术的新研究人员 目的：探讨肾脏疾病的病因和后果。本次研讨会的计划是 将概述非侵入性检测和生物标记物需求的临床演示与 介绍了基于对比的磁共振成像的最新进展，弛豫测量，扩散，和 弹性成像、多核应用、临床前动物研究和人工关节的应用 智能技术。研讨会的重点是下一代，研讨会将包括 为受训者和新调查人员提供的指导课程，称为“与专家见面”。这些指导 会议将提供关于临床试验设计、资金和法规的具体信息，以及 关于可用的成像后处理软件的动手“我是如何做到的”课程。这个工作坊是 专为研究人员(包括博士生和博士后)、临床医生(例如，放射科医生、 肾病学家、肾移植外科医生)；磁共振技术专家；政府监管专家；非营利性组织 和对肾脏疾病早期诊断感兴趣的学术团体；以及ISMRM的成员， ASN和PARENCHIMA.该计划是为高级调查人员和初级科学家设计的，具有 为对继续医学教育感兴趣的与会者提供相关主题。它介绍了以下知识 使用定量核磁共振诊断和监测一系列医疗状况的新方法， 例如，肾组织损伤、氧合、造影剂和非造影剂灌注、肾移植前和移植后 移植评估等。我们将提供在临床试验和 实践，以及数据分析指南。我们计划的一个关键要素是接触妇女和 鼓励少数族裔参加我们的研讨会。这次研讨会将是第一次 北美，但在此之前，英国肾脏成像协会曾联合举办过三次欧洲会议 网络(UKRIN)和成本行动“慢性肾脏疾病核磁共振生物标记物”(PARENCHIMA)。 (https://renalmri.org).)这些以往的研讨会有150多人参加， 主讲人。因此，我们期待社会各界对拟议的研讨会产生浓厚的兴趣。

Project Summary/ Abstract Functional renal MRI biomarkers are underused in research and clinical practice due to the need for dedicated in-house expertise and development. Transferring solutions to other centers is therefore a challenge, leading to a significant duplication of efforts, a lack of standardization in the methods, and difficulties in comparing results between centers. This also limits commercial buy-in, hinders the establishment of multi-center trials, and overall impedes the translation of these biomarkers into clinical practice. Our proposed workshop (https://www.ismrm.org/workshops/2021/Renal/) aims to bridge this gap. The purpose of this workshop is to bring together internationally recognized scientists and clinicians with new investigators who are currently developing and applying advanced renal MRI techniques in order to investigate the causes and consequences of kidney disease. The program of this workshop integrates clinical presentations outlining the needs for non-invasive testing and biomarkers with presentations on recent advances in contrast-based MRI, new applications of relaxometry, diffusion, and elastography, multinuclear applications, pre-clinical animal studies, and application of artificial intelligence techniques. With an important focus on the next generation, the workshop will include mentoring sessions for trainees and new investigators, called “Meet the Experts.” These mentoring sessions will provide specific information on clinical trials design, funding and regulations, as well as a hands-on “how I do it” sessions on available imaging post-processing software. This workshop is designed for researchers (including Ph.D. students and postdocs); clinicians (e.g., radiologists, nephrologists, renal transplant surgeons); MR technologists; government regulatory experts; nonprofit and academic groups interested in early diagnosis of renal disease; as well as members of the ISMRM, ASN, and PARENCHIMA. The program is designed for both senior investigators and junior scientists, with relevant topics for our attendees interested in continuing medical education. It presents knowledge of new methodologies in using quantitative MRI to diagnose and monitor a range of medical conditions, e.g., renal tissue injury, oxygenation, contrast and non-contrast perfusion, renal pre-transplant and post- transplant evaluations, etc. We will provide methods for utilizing this knowledge in clinical trials and practice, as well as guidance on data analysis. A key element of our plan is to reach out to women and minorities to encourage them to attend and participate in our workshop. This workshop will be a first in North America but follows three previous European meetings co-organized by the UK Renal Imaging Network (UKRIN) and the COST action “MRI Biomarkers for Chronic Kidney Disease” (PARENCHIMA). (https://renalmri.org). These previous workshops were attended by over 150 participants and presenters. Thus, we expect robust interest in the community for the proposed workshop.